AML Maintenance Part 2: a metaMORPHOsis?
In the second portion of our two part-series on AML maintenance, Anthony and Bernie delve into the studies of post-transplant FLT3 inhibitor maintenance. We discuss the controversial MORPHO study of gilteritinib and whether these results will change practice! Sorafenib observational study: https://pubmed.ncbi.nlm.nih.gov/30809038/ SORMAIN (sorafenib): https://pubmed.ncbi.nlm.nih.gov/32673171/ Chinese Sorafenib Phase III: https://pubmed.ncbi.nlm.nih.gov/32791048/ RADIUS (midostaurin): https://pubmed.ncbi.nlm.nih.gov/33288862/ AMLSG 16-10 (midostaurin): https://pubmed.ncbi.nlm.nih.gov/30563875/ MORPHO (EHA abstract): https://library.ehaweb.org/eha/2023/eha2023-congress/391322/faculty.presenters.bmt-ctn.1506.28morpho29.a.randomized.trial.of.the.flt3.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Dmorpho